Ghrelin function in human obesity and type 2 diabetes: a concise review

Obesity Reviews

Volumn 18, Issue 2, 2017, Pages 140-148

  Churm, R ^a   Davies, J S ^a   Stephens, J W ^a   Prior, S L ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Ghrelin; obesity; type 2 diabetes

Indexed keywords

GHRELIN; LIPID;

ADIPOCYTE; ADIPOGENESIS; CELL ENERGY; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; LIPID HOMEOSTASIS; METABOLIC DISORDER; NERVE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; REVIEW; ANIMAL; BLOOD; LIPID METABOLISM; METABOLISM; PHYSIOLOGY;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; DIABETES MELLITUS, TYPE 2; GHRELIN; HUMANS; HYPOTHALAMUS; LIPID METABOLISM; OBESITY; PANCREAS;

EID: 85008931469     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12474     Document Type: Review

References (88)

1. Mishra AK, Dubey V, Ghosh AR. Obesity: an overview of possible role (s) of gut hormones, lipid sensing and gut microbiota. Metabolism 2016; 65: 48–65.
2. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495–522.
3. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511–25.
4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656–60.
5. Gnanapavan S, Kola B, Bustin SA et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988–88.
6. Müller T, Nogueiras R, Andermann M et al. Ghrelin. Mol Metab 2015; 4: 437–60.
7. Dixit VD, Schaffer EM, Pyle RS et al. Ghrelin inhibits leptin-and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57.
8. Garin MC, Burns CM, Kaul S, Cappola AR. The human experience with ghrelin administration. J Clin Endocrinol Metab 2013; 98: 1826–37.
9. Angelidis G, Valotassiou V, Georgoulias P. Current and potential roles of ghrelin in clinical practice. J Endocrinol Invest 2010; 33: 823–38.
10. Date Y, Murakami N, Toshinai K et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002; 123: 1120–8.
11. Rodriguez A, Gomez-Ambrosi J, Catalan V et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 2009; 33: 541–52.
12. Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008; 132: 387–96.
13. Banks WA, Tschöp M, Robinson SM, Heiman ML. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002; 302: 822–7.
14. Serby MD, Zhao H, Szczepankiewicz BG et al. 2, 4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. J Med Chem 2006; 49: 2568–78.
15. Banks WA, Burney BO, Robinson SM. Effects of triglycerides, obesity, and starvation on ghrelin transport across the blood–brain barrier. Peptides 2008; 29: 2061–5.
16. Tsubone T, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Ghrelin regulates adiposity in white adipose tissue and UCP1 mRNA expression in brown adipose tissue in mice. Regul Pept 2005; 130: 97–103.
17. Whittle AJ, López M, Vidal-Puig A. Using brown adipose tissue to treat obesity–the central issue. Trends Mol Med 2011; 17: 405–11.
18. Mano-Otagiri A, Iwasaki-Sekino A, Nemoto T et al. Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats. Regul Pept 2010; 160: 81–90.
19. Cai H, Cong W-N, Daimon CM et al. Altered lipid and salt taste responsivity in ghrelin and GOAT null mice. PLoS One 2013; 8: e76553.
20. Masuda Y, Tanaka T, Inomata N et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000; 276: 905–8.
21. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714–9.
22. Brunetti L, Recinella L, Orlando G, Michelotto B, Di Nisio C, Vacca M. Effects of ghrelin and amylin on dopamine, norepinephrine and serotonin release in the hypothalamus. Eur J Pharmacol 2002; 454: 189–92.
23. Broglio F, Gottero C, Benso A et al. Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans. Clin Endocrinol (Oxf) 2003; 58: 92–8.
24. Kirchner H, Gutierrez JA, Solenberg PJ et al. GOAT links dietary lipids with the endocrine control of energy balance. Nat Med 2009; 15: 741–5.
25. Liu J, Prudom CE, Nass R et al. Novel ghrelin assays provide evidence for independent regulation of ghrelin acylation and secretion in healthy young men. J. Clin. Endocrinol. Metab 2008; 93: 1980–7.
26. Broglio F, Arvat E, Benso A et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J. Clin. Endocrinol. Metab 2001; 86: 5083–83.
27. Chabot F, Caron A, Laplante M, St-Pierre DH. Interrelationships between ghrelin, insulin and glucose homeostasis: physiological relevance. World J Diabetes 2014; 5: 328.
28. Chen L, Xing T, Wang M et al. Local infusion of ghrelin enhanced hippocampal synaptic plasticity and spatial memory through activation of phosphoinositide 3-kinase in the dentate gyrus of adult rats. EUR J Neurosci 2011; 33: 266–75.
29. Scerif M, Goldstone AP, Korbonits M. Ghrelin in obesity and endocrine diseases. Mol Cell Endocrinol 2011; 340: 15–25.
30. Cowley MA, Smith RG, Diano S et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37: 649–61.
31. Arnold M, Mura A, Langhans W, Geary N. Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat. J Neurosci 2006; 26: 11052–60.
32. Le Roux C, Neary N, Halsey T et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J. Clin. Endocrinol. Metab 2005; 90: 4521–4.
33. English P, Ghatei M, Malik I, Bloom S, Wilding J. Food fails to suppress ghrelin levels in obese humans. J. Clin. Endocrinol. Metab. 2002; 87: 2984–84.
34. Alvarez-Castro P, Isidro ML, Garcia-Buela J et al. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients. Clin Endocrinol (Oxf) 2004; 61: 250–5.
35. Huda M, Dovey T, Wong S et al. Ghrelin restores ‘lean-type'hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects. Int J Obes (Lond) 2009; 33: 317–25.
36. Briggs DI, Enriori PJ, Lemus MB, Cowley MA, Andrews ZB. Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. Endocrinology 2010; 151: 4745–55.
37. Patterson M, Bloom SR, Gardiner JV. Ghrelin and appetite control in humans—potential application in the treatment of obesity. Peptides 2011; 32: 2290–4.
38. DelParigi A, Tschöp M, Heiman ML et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader–Willi syndrome. J. Clin. Endocrinol. Metab 2002; 87: 5461–4.
39. Sato T, Ida T, Nakamura Y, Shiimura Y, Kangawa K, Kojima M. Physiological roles of ghrelin on obesity. Obes Res Clin Pract 2014; 8: e405–13.
40. Zorrilla EP, Iwasaki S, Moss JA et al. Vaccination against weight gain. Proc Natl Acad Sci 2006; 103: 13226–31.
41. Hornby P. Designing Spiegelmers to antagonise ghrelin. Gut 2006; 55: 754–5.
42. Asakawa A, Inui A, Kaga T et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003; 52: 947–52.
43. Maletínská L, Matyšková R, Maixnerová J et al. The Peptidic GHS-R antagonist [D-Lys 3] GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity. Mol Cell Endocrinol 2011; 343: 55–62.
44. Holst B, Schwartz TW. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends Pharmacol Sci 2004; 25: 113–7.
45. Petersen PS, Woldbye DP, Madsen AN et al. In vivo characterization of high basal signaling from the ghrelin receptor. Endocrinology 2009; 150: 4920–30.
46. Lee JH, Lin L, Xu P et al. Neuronal deletion of ghrelin receptor almost completely prevents diet-induced obesity. Diabetes 2016; 65: 2169–78.
47. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin—a hormone with multiple functions. Front Neuroendocrinol 2004; 25: 27–68.
48. Knebel B, Haas J, Hartwig S et al. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS One 2012; 7: e31812.
49. Davies JS, Kotokorpi P, Eccles SR et al. Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. Mol Endocrinol 2009; 23: 914–24.
50. Kennedy MA, Barrera GC, Nakamura K et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005; 1: 121–31.
51. Fielding CJ, Fielding PE. Cellular cholesterol efflux. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 2001; 1533: 175–89.
52. Vaughan AM, Oram JF. ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J. Biol. Chem 2005; 280: 30150–7.
53. Ma AZ, Song ZY, Zhang Q. Cholesterol efflux is LXRalpha isoform-dependent in human macrophages. BMC Cardiovasc Disord 2014; 14: 80.
54. Wagner BL, Valledor AF, Shao G et al. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol Cell Biol 2003; 23: 5780–9.
55. Porteiro B, Díaz-Ruíz A, Martínez G et al. Ghrelin requires p53 to stimulate lipid storage in fat and liver. Endocrinology 2013; 154: 3671–9.
56. Velásquez DA, Martínez G, Romero A et al. The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 2011; 60: 1177–85.
57. Kola B, Wittman G, Bodnár I et al. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release. FASEB J 2013; 27: 5112–21.
58. Demers A, Caron V, Rodrigue-Way A, Wahli W, Ong H, Tremblay A. A concerted kinase interplay identifies PPARγ as a molecular target of ghrelin signaling in macrophages. 2009.
59. Schultz JR, Tu H, Luk A et al. Role of LXRs in control of lipogenesis. Genes Dev 2000; 14: 2831–8.
60. Benso A, St-Pierre D, Prodam F et al. Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. Eur J Endocrinol 2012; 166: 911–6.
61. Gasco V, Beccuti G, Marotta F et al. Endocrine and metabolic actions of ghrelin. 2010.
62. Kageyama H, Funahashi H, Hirayama M et al. Morphological analysis of ghrelin and its receptor distribution in the rat pancreas. Regul Pept 2005; 126: 67–71.
63. Delhanty P, van der Lely AJ. Ghrelin and glucose homeostasis. Peptides 2011; 32: 2309–18.
64. Dezaki K, Hosoda H, Kakei M et al. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in β-cells implication in the glycemic control in rodents. Diabetes 2004; 53: 3142–51.
65. DiGruccio MR, Mawla AM, Donaldson CJ et al. Comprehensive alpha, beta and delta cell transcriptomes reveal that ghrelin selectively activates delta cells and promotes somatostatin release from pancreatic islets. Mol Metab 2016; 5: 449–58.
66. Broglio F, Gottero C, Benso A et al. Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J. Clin. Endocrinol. Metab 2003; 88: 4268–72.
67. Guido M, Romualdi D, De Marinis L et al. Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin. Fertil Steril 2007; 88: 125–30.
68. Dezaki K, Sone H, Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008; 118: 239–49.
69. Arosio M, Ronchi CL, Gebbia C, Cappiello V, Beck-Peccoz P, Peracchi M. Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels. J. Clin. Endocrinol. Metab 2003; 88: 701–4.
70. Vestergaard ET, Hansen TK, Gormsen LC et al. Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. Am J Physiol Endocrinol Metab 2007; 292: E1829–36.
71. Gauna C, Kiewiet RM, Janssen JA et al. Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab 2007; 293: E697–704.
72. Delhanty PJ, Neggers SJ, van der Lely AJ. Should we consider des-acyl ghrelin as a separate hormone and if so, what does it do? In: How Gut and Brain Control Metabolism. Karger Publishers: Basel, 2014, pp. 163–74.
73. Delhanty P, van der Lely A-J. Ghrelin and glucose homeostasis. Peptides 2011; 32: 2309–18.
74. Katsuki A, Urakawa H, Gabazza EC et al. Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Eur J Endocrinol 2004; 151: 573–7.
75. Lam TK, Van de Werve G, Giacca A. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites. Am J Physiol Endocrinol Metab 2003; 284: E281–90.
76. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians 1999; 111: 241–8.
77. Vestergaard ET, Buhl M, Gjedsted J et al. Acute peripheral metabolic effects of intraarterial ghrelin infusion in healthy young men. J Clin Endocrinol Metab 2010; 96: 468–77.
78. Maumus M, Sengenes C, Decaunes P et al. Evidence of in situ proliferation of adult adipose tissue-derived progenitor cells: influence of fat mass microenvironment and growth. J Clin Endocrinol Metab 2008; 93: 4098–106.
79. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010; 17: 332–41.
80. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006; 116: 607–14.
81. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213–9.
82. Esler WP, Rudolph J, Claus TH et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 2007; 148: 5175–85.
83. Dezaki K, Yada T. Islet b-cell ghrelin signaling for inhibition of insulin secretion. Methods Enzymol 2012; 514: 317–31.
84. Tong J, Prigeon RL, Davis HW et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010; 59: 2145–51.
85. Meyer C. Final answer: ghrelin can suppress insulin secretion in humans, but is it clinically relevant? Diabetes 2010; 59: 2726–8.
86. Bayliss JA, Lemus MB, Stark R et al. Ghrelin-AMPK signaling mediates the neuroprotective effects of calorie restriction in Parkinson's disease. J Neurosci 2016; 36: 3049–63.
87. Hornsby AK, Redhead YT, Rees DJ et al. Short-term calorie restriction enhances adult hippocampal neurogenesis and remote fear memory in a Ghsr-dependent manner. Psychoneuroendocrinology 2016; 63: 198–207.
88. Kent BA, Beynon AL, Hornsby AK et al. The orexigenic hormone acyl-ghrelin increases adult hippocampal neurogenesis and enhances pattern separation. Psychoneuroendocrinology 2015; 51: 431–9.